Q-omics provides the consensus-scored DMXL2 profile across patient tissues and cancer cell-line models. DMXL2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, DMXL2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, DMXL2 protein abundance shows 30,965 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, HNSC, and GBM as cancer lineages where DMXL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DMXL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DMXL2 survival associations across molecular data types. DMXL2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DMXL2 RNA expression–survival associations across cancer types. High DMXL2 expression shows unfavorable associations in KICH, UVM, CESC, STAD, MESO and LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for DMXL2 RNA expression.
This table summarizes DMXL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DMXL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DMXL2 shows lower tumor expression in LUSC and higher tumor expression in HNSC, STAD, LIHC, KIRC and CHOL. The HNSC box plot shows higher DMXL2 RNA expression in tumor versus normal tissue (log2 FC = +1.080, t-test p < 0.001).
This table shows molecular features associated with DMXL2 in patient tissues and cancer cell lines. In patient samples, DMXL2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DMXL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
